[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Clinical Review
Clinician's Corner
July 8, 2009

Adiponectin Levels and Risk of Type 2 Diabetes: A Systematic Review and Meta-analysis

Author Affiliations

Author Affiliations: Departments of Epidemiology (Drs Li and van Dam) and Nutrition (Drs Shin, Ding, and van Dam), Harvard School of Public Health, Boston, Massachusetts; Framingham Union Hospital Metro West Medical Center, Framingham, Massachusetts (Dr Shin); and Channing Laboratory, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston (Dr van Dam).

JAMA. 2009;302(2):179-188. doi:10.1001/jama.2009.976

Context The association of obesity with development of type 2 diabetes may be partly mediated by altered secretion of adipokines by adipose tissue. Greater adiposity down-regulates secretion of adiponectin, an adipokine with anti-inflammatory and insulin-sensitizing properties. The strength and consistency of the relation between plasma adiponectin and risk of type 2 diabetes is unclear.

Objective To systematically review prospective studies of the association of plasma adiponectin levels and risk of type 2 diabetes.

Data Sources A systematic search of the MEDLINE, EMBASE, and Science Citation Index Expanded databases using adiponectin and diabetes and various synonyms and reference lists of retrieved articles up to April 10, 2009.

Study Selection We included prospective studies with plasma adiponectin levels as the exposure and incidence of type 2 diabetes as the outcome variable.

Data Extraction Two reviewers independently extracted data and assessed study quality. Generalized least-squares trend estimation was used to assess dose-response relationships. Pooled relative risks and 95% confidence intervals were calculated using random-effects models to incorporate between-study variation.

Results Thirteen prospective studies with a total of 14 598 participants and 2623 incident cases of type 2 diabetes were included in the meta-analysis. Higher adiponectin levels were monotonically associated with a lower risk of type 2 diabetes. The relative risk of type 2 diabetes was 0.72 (95% confidence interval, 0.67-0.78) per 1–log μg/mL increment in adiponectin levels. This inverse association was consistently observed in whites, East Asians, Asian Indians, African Americans, and Native Americans and did not differ by adiponectin assay, method of diabetes ascertainment, duration of follow-up, or proportion of women. The estimated absolute risk difference (cases per 1000 person-years) per 1–log μg/mL increment in adiponectin levels was 3.9 for elderly Americans and 30.8 for Americans with impaired glucose tolerance.

Conclusion Higher adiponectin levels are associated with a lower risk of type 2 diabetes across diverse populations, consistent with a dose-response relationship.